Ramatroban is a potent human thromboxane receptor (hTP) antagonist with an IC ₅₀ of 18 nM in a human TP binding assay. Ramatroban inhibits prostaglandin D ₂ receptor DP2 (CRTH2) with an IC ₅₀ of 113 nM in a human DP2 binding assay. Ramatroban also inhibits human CYP isoform CYP2C9 with an IC ₅₀ of 15 μM. Ramatroban is a selective thromboxane-type prostanoid (TP) receptor antagonist. PGD ₂ -stimulated human eosinophil migration is shown to be mediated exclusively through activation of CRTH2, and surprisingly, these effects are completely inhibited by Ramatroban. Ramatroban is an antagonist for CRTH2, and inhibits PGD ₂ -induced migration of eosinophils via CRTH2 blockade. ³ H-labeled PGD ₂ binds to a single site on CRTH2 transfectants with high affinity (K _D =6.3 nM, B _max =450 pM). Nonlabeled PGD ₂ inhibits the binding of ³ H-labeled PGD ₂ to CRTH2 transfectants in a concentration-dependent manner with an EC ₅₀ value of 2.7 nM. Ramatroban shows significant inhibitory effects on the binding of ³ H-labeled PGD ₂ to CRTH2, albeit with much lower potency (IC ₅₀ =100 nM). Ramatroban also inhibits PGD ₂ -induced Ca ²⁺ mobilization in CRTH2 transfectants to almost the same extent with an IC ₅₀ value of 30 nM. Ramatroban completely inhibits the PGD ₂ -induced migration of eosinophils in a concentration-dependent manner with an IC ₅₀ value of 170 nM.

Ramatroban is an orally bioavailable small molecule antagonist of CRTH2. Systemic administration of Ramatroban (30 mg/kg) in CRTH2 ^+/+ mice produces the same effects as seen in CRTH2 deficiency. Ramatroban completely blocks LPS-induced decreases in social and object exploratory behavior (p<0.01). In addition, tumor-impaired social interaction and object exploratory behavior in CRTH2 ^+/+ mice are completely reversed by a single injection of Ramatroban, even when the tumor is enlarged.